HCWB supply chain intelligence for HCW Biologics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
HCW Biologics Inc. (HCWB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| WUGEN | WUGEN | 92% | The Company entered a development supply agreement with Wugen to provide it with clinical development materials needed for research and clinical development in the first quarter of 2021 |
| BE-K | BE-K | 80% | the Company received a summons and a copy of a complaint filed by BE&K in the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from INAB graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from INAB g… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from JNJ grap… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from NKTR g… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from SNYN… |
| B-I-CONTRACTORS-INC | B-I-CONTRACTORS-INC | 70% | B&I, one of the defendants in the BE&K Complaint, filed a motion for summary judgment |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SQUARE-GATE-CAPITAL-MASTER-FUND-LLC-SERIES-4 | SQUARE-GATE-CAPITAL-MASTER-FUND-LLC-SERIES-4 | 92% | Under the Equity Purchase Agreement, the Company will have the right, but not the obligation, to sell to Square Gate, and Square Gate will have the obligation to purchase from the Company, up to $ 20… |
| WY-BIOTECH-CO-LTD | WY-BIOTECH-CO-LTD | 92% | On February 13, 2026, HCW Biologics Inc. and WY Biotech Co., Ltd. (“WY Biotech”), a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapie… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from HCWB graph: and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete … |
| JNJ | Johnson & Johnson | 72% | and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete the Phase 1 or Phase 2 clinical trials we have planned for HCW9302 during 2026 an… |
| NKTR | Nektar Therapeutics | 72% | and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete the Phase 1 or Phase 2 clinical trials we have planned for HCW9302 during 2026 an… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from HCWB graph: and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete… |
| SNYNF | Sanofi | 72% | and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete the Phase 1 or Phase 2 clinical trials we have planned for HCW9302 during 2026 an… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from HCWB graph: and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complet… |
| ABBVIE-AMGEN-ASTRAZENECA-MEDIMMUNE-BRISTOL-MYERS | ABBVIE-AMGEN-ASTRAZENECA-MEDIMMUNE-BRISTOL-MYERS | 62% | and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete the Phase 1 or Phase 2 clinical trials we have planned for HCW9302 during 2026 an… |
| BEIJING-TRIMMUNE-BIOTECH-CO-LTD | BEIJING-TRIMMUNE-BIOTECH-CO-LTD | 62% | and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete the Phase 1 or Phase 2 clinical trials we have planned for HCW9302 during 2026 an… |
| B-I-CONTRACTORS-INC | B-I-CONTRACTORS-INC | 62% | , manufacturing and distribution. Accordingly, we will need to obtain substantial additional funding for our continuing operations. If we are unable to raise capital when needed or on attractive term… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HCWB-DEBT | Debt stack $119,398 | 90% | Market cache reports total debt of $119,398. |
| HCWB-DEBT-9996 | Warrants outstanding: 2477292 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| HCWB-DEBT-9997 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-06-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| HCWB-OWNER-DRW-SECURITIES-LLC | DRW Securities, LLC | 95% | 13F/ownership overlay lists DRW Securities, LLC; shares held 35,281; ownership 1.08%; value $33,890; as of 2025-12-31. |
| HCWB-OWNER-J-W-COLE-ADVISORS-INC | J.W. Cole Advisors, Inc. | 95% | 13F/ownership overlay lists J.W. Cole Advisors, Inc.; shares held 12,500; ownership 0.38%; value $12,007; as of 2025-12-31. |
| HCWB-OWNER-CITADEL-ADVISORS-LLC | Citadel Advisors Llc | 95% | 13F/ownership overlay lists Citadel Advisors Llc; shares held 22,158; ownership 0.68%; value $21,284; as of 2025-12-31. |
| HCWB-OWNER-HRT-FINANCIAL-LP | HRT Financial LP | 95% | 13F/ownership overlay lists HRT Financial LP; shares held 266,393; ownership 3.96%; value $324,999; as of 2026-03-31. |
| HCWB-OWNER-SUSQUEHANNA-INTERNATIONAL-GROUP-LLP | Susquehanna International Group, LLP | 95% | 13F/ownership overlay lists Susquehanna International Group, LLP; shares held 20,071; ownership 0.61%; value $19,280; as of 2025-12-31. |
| HCWB-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 14,037; ownership 0.43%; value $13,483; as of 2025-12-31. |
| HCWB-OWNER-ARMISTICE-CAPITAL-LLC | Armistice Capital, LLC | 95% | 13F/ownership overlay lists Armistice Capital, LLC; shares held 300,180; ownership 9.15%; value $288,352; as of 2025-12-31. |
| HCWB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | Vanguard Capital Management LLC | 95% | 13F/ownership overlay lists Vanguard Capital Management LLC; shares held 12,023; ownership 0.18%; value $4,051; as of 2026-03-31. |
| HCWB-OWNER-TOWER-RESEARCH-CAPITAL-LLC-TRC | Tower Research Capital LLC (TRC) | 95% | 13F/ownership overlay lists Tower Research Capital LLC (TRC); shares held 4,504; ownership 0.14%; value $4,326; as of 2025-12-31. |
| HCWB-OWNER-VIRTU-FINANCIAL-LLC | Virtu Financial LLC | 95% | 13F/ownership overlay lists Virtu Financial LLC; shares held 47,809; ownership 0.71%; value $58,326; as of 2026-03-31. |
| HCWB-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 15,426; ownership 0.47%; value $14,818; as of 2025-12-31. |
| HCWB-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 1,739; ownership 0.05%; value $1,670; as of 2025-12-31. |
| HCWB-OWNER-GOLDEN-STATE-WEALTH-MANAGEMENT-LLC | Golden State Wealth Management, Llc | 95% | 13F/ownership overlay lists Golden State Wealth Management, Llc; shares held 10,000; ownership 0.15%; value $3,370; as of 2026-03-31. |
| HCWB-OWNER-CITIGROUP-INC | Citigroup Inc. | 95% | 13F/ownership overlay lists Citigroup Inc.; shares held 10,528; ownership 0.16%; value $3,547; as of 2026-03-31. |
| HCWB-OWNER-JANE-STREET-GROUP-LLC | Jane Street Group, LLC | 95% | 13F/ownership overlay lists Jane Street Group, LLC; shares held 14,134; ownership 0.21%; value $4,763; as of 2026-03-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |